Tata Chemicals Limited

The global soda ash market is currently grappling with significant oversupply, primarily driven by new low-cost natural soda ash capacities in China. Management noted that Chinese soda ash prices have plummeted by 54% since Q3 FY23, reaching approximately CNY 1,200. This has intensified competition in Southeast Asia, forcing Tata Chemicals to pause certain US export shipments that fall below a $155-$160 realization floor.

Despite global headwinds^🌐, the India standalone business grew revenue by 3% to ₹1,204 crores. Performance was bolstered by higher volumes and operational efficiencies, with Silica sales volumes up 15% and FOS up 9%. Management expects India to remain a net importer, justifying continued investment in domestic capacity like the 350 KT dense ash expansion at Mithapur.

The UK operations faced a setback this quarter due to an unplanned stoppage at the salt plant and severe winter storms, pushing the break-even target to Q4 FY26. While management had previously guided for ₹250 crores of EBITDA in FY26, they admitted to being roughly six months behind schedule. However, fixed cost savings are materializing, and the pharmaceutical salt unit is scaling up.

Tata Chemicals is aggressively shifting its focus toward non-cyclical, value-added segments. This is evidenced by the ₹515 crore investment in a greenfield iodized salt facility in Tamil Nadu and the acquisition of Novabay Singapore. These moves aim to reduce dependency on the volatile commodity soda ash cycle and capture higher-margin pharmaceutical and food-grade markets.

The company is adopting a disciplined approach to capital allocation, focusing almost exclusively on India for new capacity. Total approved capex for salt, silica, and soda ash exceeds ₹1,400 crores, with targeted project returns above 16%. Despite a negative operating cash flow of ₹700 crores over nine months (partially due to forex movements), management remains committed to maintaining balance sheet strength.